Saturday, November 21, 2026
Home Blog Page 1074

Discovery of cancer risk associations for six novel genes

0

Scientists at deCODE genetics/Amgen, and their collaborators have discovered six novel genes with rare germline variants that associate with cancer risk. The findings are published today in Nature Genetics under the title “Gene-based burden tests of rare germline variants identify six cancer susceptibility genes”.

A subset of cancers arises in individuals who are born with rare sequence variants that significantly alter their cancer risk. The discovery of such variants, like those in the BRCA1– and BRCA2 genes, has led to improved early cancer detection and the development of targeted therapies, ultimately reducing the cancer burden and improving prognosis of those carrying these mutations.

In this study, the scientists analysed three large genetic datasets from individuals of European descent, including 130,991 cancer patients and 733,486 controls. Through a gene-based burden association analysis across 22 different cancer types, they found four novel genes associated with a risk of developing cancer; the pro-apoptotic BIK for prostate cancer, the autophagy involved ATG12 for colorectal cancer, TG for thyroid cancer, and CMTR2 for both lung cancer and cutaneous melanoma. The relative increase in cancer risk conferred by these variants was substantial (90-295%), but it should be noted that the design of the study does not allow accurate assessment of absolute lifetime cancer risk.

Abyei Demands Self-rule as Sudan Conflict Stalls Referendum

0

Leaders of the Dinka Ngok in Abyei are demanding self-governance as the ongoing conflict in Sudan dashes hopes for a referendum to determine the disputed region’s future. In a memorandum to the UN peacekeeping force in Abyei (UNISFA), the Dinka Ngok, who are the main inhabitants of the region, called for international support for self-rule during an interim period until Sudan and South Sudan can agree on Abyei’s final status. The 2005 Comprehensive Peace Agreement granted Abyei special status and promised a referendum to decide whether it would join Sudan or South Sudan. However, the vote has been repeatedly delayed due to disagreements over voter eligibility, primarily the participation of the nomadic Misseriya tribe…With Sudan engulfed in conflict and South Sudan hesitant to act unilaterally, the Dinka Ngok see little chance of a resolution in the near future. They warn that Abyei, already “ravaged by decades of violence,” risks becoming a battleground. (Sudan Tribune)

Abyei Demands Self-rule as Sudan Conflict Stalls Referendum

0

Leaders of the Dinka Ngok in Abyei are demanding self-governance as the ongoing conflict in Sudan dashes hopes for a referendum to determine the disputed region’s future. In a memorandum to the UN peacekeeping force in Abyei (UNISFA), the Dinka Ngok, who are the main inhabitants of the region, called for international support for self-rule during an interim period until Sudan and South Sudan can agree on Abyei’s final status. The 2005 Comprehensive Peace Agreement granted Abyei special status and promised a referendum to decide whether it would join Sudan or South Sudan. However, the vote has been repeatedly delayed due to disagreements over voter eligibility, primarily the participation of the nomadic Misseriya tribe…With Sudan engulfed in conflict and South Sudan hesitant to act unilaterally, the Dinka Ngok see little chance of a resolution in the near future. They warn that Abyei, already “ravaged by decades of violence,” risks becoming a battleground. (Sudan Tribune)

‘People Didn’t Believe Africa Could Be a Source of Innovation’: How the Continent Holds the Key to Future Drug Research

0

Africa has the greatest variety in human genes anywhere on the planet but the world is failing to capitalise on it, according one of the continent’s leading scientists, Prof Kelly Chibale, a man determined to change that…About 18% of the global population lives in Africa – a proportion set to rise over the next few decades – and it accounts for 20% of the global disease burden. But only 3% of clinical trials take place on the continent, and most of those in just two countries – South Africa and Egypt…Testing a drug in people with a wider variety of genes, rather than the historic standard of a Caucasian man, means the frequency and amount of a drug given to patients can be better calibrated for everyone before it gets to market. Some global regulators now require genetic diversity in trials before they will approve medicines…The 2023 recipient of the Royal Society’s Africa prize, Chibale…leads the H3D research centre at the University of Cape Town, a unit he founded in 2011, which is working on drugs to fight diseases such as malaria and tuberculosis, and combat antimicrobial resistance – conditions that predominantly affect people in Africa. (The Guardian)